Systematic review and meta-analysis on the efficacy of GLP-1-based therapies on MASLD and MASH. academic.oup.com/jcem/article/1…

On the cover, a new analysis of the SELECT trial confirms semaglutide lowers the risk of major heart problems in people who are overweight or obese and already have heart disease, even if they don’t have diabetes. 🫀 Read this & more in our new issue: hubs.li/Q03S8tKK0

Amiloidosis Cardíaca en adultos mayores con enfoque en la fragilidad. 🫀💥👴 ✨️STATE-OF-THE-ART REVIEW JACC Journals 💯 🔶️La amiloidosis cardíaca en adultos mayores exige un enfoque integral que combine cardiología y geriatría. La fragilidad debe considerarse un objetivo

Agree… underuse of SGLT2i in true CKD is shocking.

Ya hay muchos estudios y publicaciones hablando de sinergia entre ISGLT2 y ar -GLP1 ! Sin duda el beneficio cardiovascular, cardiorrenal y en insuficiencia cardiaca es muy notorio!

Para revisar ✍️! Muy interesante

🚨 New breakthrough in prevention! 👉In the VESALIUS‑CV trial, Evolocumab added to high-intensity statin therapy reduced major adverse cardiovascular events (MACE) by 25% (HR 0.75; 95% CI 0.65-0.86) over ~4.6 years in patients who had no prior MI or stroke. 👉Absolute risk

Presented at #AHA25: In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. Full ADAPT

OPTIMA-AF trial: In AF patients undergoing PCI with EES, 1-month therapy with DOAC + P2Y12 inhibitor was non-inferior for preventing ischemia and superior for reducing bleeding compared to 12-month therapy. #AHA25 View the slides here: clinicaltrialresults.org/wp-content/upl…

CLOSURE-AF results presented at #AHA25

OCEAN results presented at #AHA25

I have first hand knowledge that patients in the US are offered LAAC as an alternative to oral AC. For things as mundane as bruising, the potential of a fall and ...gulp...cost of DOAC. CLOSURE AF says this is wrong. It's always been wrong, but now we know. #AHA25

Studies like OCEAN from #AHA25 are reshaping strategies for managing #AFib, exploring topics like ongoing anticoagulation post-catheter ablation; optimal antithrombotic approaches after #cvPCI; and LAAC vs. medical therapy in high-risk patients. More ➡️ bit.ly/47vGSTD

Publicado el Vesalius Evolocumab en pacientes sin eventos previos, pero de muy alto riesgo La reducción fue significativa... Ahora veamos otra forma de decir lo mismo...

Get this: Coffee suppressed atrial fibrillation! Unexpected results for recurrence from a randomized trial in participants after cardioversion from AF #AHA25 JAMA ☕️ jamanetwork.com/journals/jama/…

NEJM rarely publishes meta-analysis (NEJM Evidence does), but this is a good one! NEJM nejm.org/doi/full/10.10…

Una cosa es decir que no hay evidencia ! Acá hay evidencia contundente: Los betabloqueadores NO deberían ser indicados en post IAM y una FEVI > del 50 % !